Intensity of and Adherence to Lipid‐Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease

Abstract

Background The effectiveness of lipid‐lowering therapy (LLT) is affected by both intensity and adherence. This study evaluated the associations of LLT intensity, adherence, and the combination of these 2 aspects of LLT management with the risk of major adverse cardiovascular events (MACE) in people with coronary heart disease. Methods and Results This is an observational study of all adults who suffered a myocardial infarction or had coronary revascularization during 2012 to 2018 and initiated LLT in Stockholm, Sweden. Study exposures were LLT adherence (proportion of days covered), LLT intensity (expected reduction of low‐density lipoprotein cholesterol), and the combined measure of adherence and intensity. At each LLT fill, adherence and intensity during the previous 12 months were calculated. The primary outcomes were MACE (nonfatal myocardial infarction or stroke and death); secondary outcomes were low‐density lipoprotein cholesterol goal attainment and individual components of MACE. We studied 20 490 patients aged 68±11 years, 75% men, mean follow‐up 2.6±1.1 years. Every 10% increase in 1‐year adherence, intensity, or adherence‐adjusted intensity was associated with a lower risk of MACE (hazard ratio [HR], 0.94 [95% CI, 0.93–0.96]; HR, 0.92 [95% CI, 0.88–0.96]; and HR, 0.91 [95% CI, 0.89–0.94], respectively) and higher odds of attaining low‐density lipoprotein cholesterol goals (odds ratio [OR],1.12 [95% CI, 1.10–1.15]; OR, 1.42 [95% CI, 1.34–1.51], and OR, 1.16 [95% CI, 1.19–1.24], respectively). Among patients with good adherence (≥80%), the risk of MACE was similar with low‐moderate and high‐intensity LLT despite differences in the low‐density lipoprotein cholesterol goal attainment with the treatment intensities. Discontinuation ≥1 year increased the risk markedly (HR,1.66 [95% CI, 1.23–2.22]). Conclusions In routine care, good adherence to LLT was associated with the greatest benefit for patients with coronary heart disease. Strategies that improve adherence and use of intensive therapies could substantially reduce cardiovascular risk.

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

“…Among 20 490 adults who had an MI or coronary revascularization in Stockholm, Sweden, between 2012 and 2018 and initiated lipid-lowering therapy, the risk of MACEs was significantly lower for each 10% increase in 1-year adherence (HR, 0.94 [95% CI, 0.93–0.96]), intensity (HR, 0.92 [95% CI, 0.88–0.96]), and adherence-adjusted intensity (HR, 0.91 [95% CI, 0.89–0.94]). 81…”

Blood lipid levels mediating the effects of sex hormone-binding globulin on coronary heart disease: Mendelian randomization and mediation analysis

“…Currently, clinical trials have established statin as the cornerstone of lipid-lowering therapy for CHD 53 . Good adherence to lipid-lowering therapy and achievement of LDL-C control target can significantly reduce the occurrence of major adverse cardiovascular events in patients with CHD 54 . Of course, besides alterations in lipid levels, there are inevitably other mediators at play.…”

Association of lipid composition and unsaturated fatty acids of VLDL with atrial remodeling in metabolic syndrome

“…Lastly, how long would a statin withdraw lead to prominent changes of VLDL lipids was not determined in this study. Since statin therapy has become an indispensable treatment for primary and secondary cardiovascular event prevention, withdrawal of statin bears an important ethical concern 64 . Our study had excluded any subjects with overt cardiovascular diseases.…”